CLYM - NASDAQ
Climb Bio, Inc.
$10.91
-2.6%Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
At a Glance
Live Snapshotclym
Research Development Expenses
Last Annual Value
46.62M
3-Year CAGR
21%
5-Year CAGR
38%
10-Year CAGR
28%
Climb Bio, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Climb Bio, Inc. NASDAQ:CLYM | 46.62M | 44.6% | 14.9% | N/A | |
 Inovio Pharmaceuticals, Inc. NASDAQ:INO | 54.21M | -14.5% | -26.3% | -4.8% | |
 Spero Therapeutics, Inc. NASDAQ:SPRO | 38.47M | -9.2% | -9.8% | 3.9% | |
 Turn Therapeutics Inc. NASDAQ:TTRX | 265.57K | 228.4% | N/A | N/A | |
 Agenus Inc. NASDAQ:AGEN | 79.34M | -30.3% | -15.0% | -1.8% | |
 Anixa Biosciences, Inc. NASDAQ:ANIX | 5.07M | 2.1% | -3.9% | 12.5% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 49.06M | -25.3% | -19.1% | -5.0% | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 37.19M | -0.0% | 14.9% | N/A | |
 Context Therapeutics Inc. NASDAQ:CNTX | 31.86M | 21.5% | 53.0% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 20.53M | 97.6% | 6.2% | 15.2% | |
 Inhibikase Therapeutics, Inc. NASDAQ:IKT | 29.79M | 29.8% | 21.3% | 42.8% |
Climb Bio, Inc. Fair Value Envelope
Related Guides
Continue your CLYM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.